Amino-Acid Metabolism Disorders Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 3 studies associated with Amino-Acid Metabolism Disorders.
Here is a small sampling of Amino-Acid Metabolism Disorders studies by title:
- Cannabinol in the spotlight: Toxicometabolomic study and behavioral analysis of zebrafish embryos exposed to the unknown cannabinoid
Components of the Amino-Acid Metabolism Disorders Research Dashboard
- Dosing information available for Amino-Acid Metabolism Disorders
- Chemotype guidance for treating Amino-Acid Metabolism Disorders with cannabis
- Synopsis of cannabis research for Amino-Acid Metabolism Disorders
- Individual study details for Amino-Acid Metabolism Disorders
Ready to become a subscriber? Go to our PRICING page.
Amino-Acid Metabolism Disorders Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 3 studies associated with Amino-Acid Metabolism Disorders.
Here is a small sampling of Amino-Acid Metabolism Disorders studies by title:
- Cannabinol in the spotlight: Toxicometabolomic study and behavioral analysis of zebrafish embryos exposed to the unknown cannabinoid
Components of the Amino-Acid Metabolism Disorders Research Dashboard
- Dosing information available for Amino-Acid Metabolism Disorders
- Chemotype guidance for treating Amino-Acid Metabolism Disorders with cannabis
- Synopsis of cannabis research for Amino-Acid Metabolism Disorders
- Individual study details for Amino-Acid Metabolism Disorders
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Amino-Acid Metabolism Disorders
Description of Amino-Acid Metabolism Disorders
There is a wide variety of amino-acid metabolism disorders, also called inborn errors of metabolism. Many of these are screened for during pregnancy and at birth.
Genetic mutations (usually autosomal recessive) in metabolic pathways cause systemic issues with the processing of nutrients and excess buildup of substrates, intermediate, or final cellular waste products. These cause downstream effects in physiology that lead to identifiable patterns of health issues in multiple organ systems and behavior/intellect/development (e.g., ocular, musculoskeletal, hepatorenal, cerebral, cardiac, etc.).
One example of an amino-acid metabolism disorder is Lowe syndrome, a rare genetic disorder that affects amino-acid metabolism and is seen almost exclusively in boys. Lowe's severely affects the quality of life but most commonly the eyes, brain, muscles, and kidneys of affected boys.
Many male children with Lowe's are born with the kind of cognitive impairment, kidney problems, eye conditions (glaucoma, cataracts, blindness), muscular (poor tone) and skeletal (scoliosis, soft bones that easily fracture) problems that we are more used to seeing in some very unhealthy seniors.
Disease Classification
Condition: Amino-Acid Metabolism DisordersDisease Family:
Organ System: Nervous System, Urinary System
ICD-10 Chapter: Endocrine, Nutritional and Metabolic Diseases
ICD-10 Code: E72
Amino-Acid Metabolism Disorders Symptoms:
Drowsiness, fussiness, little appetite, throwing up, being restless or having trouble being still or quiet, changes in muscle tone, muscle weakness, coordination or balance problems, dry hair that breaks easily, learning problems, slow growth, small head, unclear speech, breathing problems, high levels of ammonia in the blood can cause intense headache especially after a high-protein meal, loss of consciousness (passing out), low body temperature, being tall and thin with long legs and arms, or long, curved fingers, chest deformities (abnormal shape), dislocation of the eye lens, failure to thrive (slow weight gain and growth), knock knees, pale hair and skin, problems with movement, redness across the cheeks, behavior and emotional problems, intellectual and developmental disabilities, high-pitched cry, trouble feeding, urine that smells like maple syrup, weight loss, bruising or bleeding, especially nosebleeds, diarrhea, bloody stools, fast heartbeat, jaundice, skin or urine that smells like cabbage, slow weight gain and growth, swollen belly or legs, trouble walking, increased tear production, sensitivity to light (photophobia), eye redness, skin lesions on the hands and feet, hyperactivityAlso known as:
Lowe Syndrome, Oculocerebrorenal syndrome, phenylketonuria, Cystinuria, Cystinosis, Hartnup disease, Cystathioninuria, Cystathioninuria, Hypermethioninemia, Homocystinuria, Sulfite oxidase deficiency, Argininaemia, Argininosuccinic aciduria, Citrullinaemia, Hyperammonemia, Glutaric aciduria, Glutaric aciduria, Disorders of amino-acid transport.Drug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
